Phase II study of the combination of ZD1839 (Iressa [gefitinib]) and celecoxib in patients with platinum-refractory non-small cell lung cancer.
Phase of Trial: Phase II
Latest Information Update: 13 Aug 2012
At a glance
- Drugs Celecoxib (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Mar 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 20 Apr 2010 Actual end date (May 2008) added as reported by ClinicalTrials.gov.
- 20 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.